Relvar/Breo “Real World” Asthma Benefits Help GSK – But Can't Remove Generic Threat
Executive Summary
Top-line data from a second patient group, asthmatics, in the Salford Lung Study indicate that switching from usual therapy to GSK’s’s Relvar Ellipta improves symptoms, but the results may not be enough to encourage switching before generic Seretide/Advair takes hold.
You may also be interested in...
Efficacy Studies Not Enough? Consider GSK's Salford Lung Study As New Model
Full results from asthma patients included in the Salford Lung Study provide powerful support for the use of “real world” effectiveness studies as a more relevant form of evidence to inform prescribing choices and improve patient outcomes, particularly in what turned out to be a general population of asthmatics that were still suffering symptoms under usual care.
Takeda Enlists Real World Evidence To Boost Marketed Entyvio
Japan’s Takeda says it has confirmed the benefits of its best-selling inflammatory bowel disease therapy Entyvio in US medical practice through the collection of real world evidence.
GSK Braces For Impact: Advair Generic Could Reduce US Brand To £1Bn
Although it’s not yet clear if an interchangeable version of the respiratory blockbuster will be approved by FDA, CEO Andrew Witty prepared investors to expect a hit, forecasting that a mid-year launch could significantly reduce revenues.